吉西他滨联合多西他赛治疗高危非肌层浸润性膀胱癌:EuroGemDoce 组结果
该研究回顾性收集 2021 至 2024 年间 12 个欧洲中心 95 例既往接受卡介苗(BCG)治疗的高危和极高危非肌层浸润性膀胱癌(NMIBC)患者,评估序贯膀胱内吉西他滨/多西他赛(Gem/Doce)治疗的肿瘤学疗效与安全性。75 例可评估患者中,1 年无病生存率为 73%,1 年高级别无病生存率为 79%,1 年无进展生存率为 95%;45% 发生不良事件,8.7% 发生严重不良事件。结论认为该方案短期肿瘤学结果令人鼓舞且耐受性良好,但随访短且各中心治疗保留时间和剂量存在差异,需前瞻性研究和随机试验进一步明确理想候选患者并标准化治疗方案。
要点
- 既往 BCG 治疗的高危/极高危 NMIBC 患者接受膀胱内 Gem/Doce 治疗,1 年无病生存率为 73%(95%CI 62-86%)。
- 1 年高级别无病生存率为 79%(95%CI 68-91%),1 年无进展生存率为 95%(95%CI 90-100%)。
- 45% 患者发生不良事件,8.7% 发生严重不良事件;中位随访 9 个月。
核心结论
- 膀胱内 Gem/Doce 方案在该既往接受 BCG 治疗的高危和极高危 NMIBC 队列中显示出有希望的短期肿瘤学结局且耐受性良好。
- 需前瞻性研究和随机试验以确定 Gem/Doce 治疗的理想候选患者并标准化治疗方案。
研究设计与样本
- 回顾性收集 2021 至 2024 年间 12 个欧洲中心 95 例接受 Gem/Doce 治疗的 NMIBC 患者数据。
- 纳入既往接受 BCG 治疗、完成全程诱导疗程并至少接受一次随访评估的患者。
- 采用 Kaplan-Meier 曲线估计 1 年无病生存率、高级别无病生存率和无进展生存率。
- 不良事件通过医疗访谈记录。
主要发现
- 75 例患者中,63 例(84%)为高危 NMIBC,12 例(16%)为极高危 NMIBC。
- 中位(四分位距)随访 9(5-14)个月,20 例(27%)复发,5 例(6.7%)接受根治性膀胱切除术。
- 1 年无病生存率为 73%(95%CI 62-86%),1 年高级别无病生存率为 79%(95%CI 68-91%),1 年无进展生存率为 95%(95%CI 90-100%)。
- 34 例(45%)发生不良事件,其中 6 例(8.7%)发生严重不良事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 随访时间短。
- 各中心之间治疗保留时间和剂量存在差异。
- 需前瞻性研究和随机试验以确定理想候选患者并标准化治疗方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the oncological efficacy and safety of sequential intravesical gemcitabine/docetaxel (Gem/Doce) therapy in a European cohort of patients with high-risk and very-high-risk non-muscle-invasive bladder cancer (NMIBC) after previous Bacillus Calmette-Guérin (BCG) treatment. MATERIALS AND METHODS: Data were retrospectively collected from 95 patients with NMIBC, treated with Gem/Doce at 12 European centres between 2021 and 2024. Patients previously treated with BCG who had completed a full induction course and received at least one follow-up evaluation were included. One-year disease-free survival (DFS), high-grade DFS and progression-free survival (PFS) were estimated using Kaplan-Meier curves. Adverse events (AEs) were recorded through medical interviews. RESULTS: Of 75 patients, 63 (84%) were classified as having high-risk and 12 (16%) as having very-high-risk NMIBC. Over a median (interquartile range) follow-up of 9 (5-14) months, 20 patients (27%) relapsed and five (6.7%) underwent radical cystectomy. The 1-year DFS was 73% (95% confidence interval [CI] 62-86%), 1-year high-grade DFS was 79% (95% CI 68-91%) and 1-year PFS was 95% (95% CI 90-100%). AEs occurred in 34 patients (45%), with six (8.7%) experiencing severe AEs. Limitations of the study include the short follow-up and variability in both treatment dwelling times and dosage across centres. CONCLUSION: The intravesical Gem/Doce regimen demonstrated promising short-term oncological outcomes and was well tolerated in this cohort of patients with high- and very-high-risk NMIBC previously treated with BCG. Prospective studies and randomised trials are awaited to define the ideal candidates for Gem/Doce therapy and to standardise treatment protocols.
引用
- Scilipoti P, Longoni M, de Angelis M, et al. Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group results. BJU Int. 2025. PMID: 39797535. doi:10.1111/bju.16645
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。